02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
20:05 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Cell culture and mouse studies suggest T cells engineered to express an anti-PSCA chimeric antigen receptor (CAR) and TGFβ-RII- and CD124-based fusion proteins could help treat pancreatic cancer. The CAR T cells...
12:49 , Mar 9, 2017 |  BC Week In Review  |  Clinical News

Rimiducid: Ph I BP-012 started

Bellicum began the open-label, U.S. Phase I BP-012 trial to evaluate BPX-601 plus rimiducid in up to 30 patients. Bellicum has rights to rimiducid from Ariad Pharmaceuticals Inc. under an amended 2006 deal (see BioCentury,...
12:49 , Mar 9, 2017 |  BC Week In Review  |  Clinical News

BPX-601: Ph I BP-012 started

Bellicum began the open-label, U.S. Phase I BP-012 trial to evaluate BPX-601 plus rimiducid (AP1903) in up to 30 patients. Bellicum has rights to rimiducid from Ariad Pharmaceuticals Inc. under an amended 2006 deal (see...
03:48 , Dec 10, 2016 |  BioCentury  |  Product Development

Rules of the road

Investigators and companies have long been devising strategies to mitigate or preempt toxicities from CAR T cell therapies without compromising efficacy. Now, data presented at the American Society of Hematology meeting suggest strategies to prevent...
07:00 , Jul 18, 2016 |  BioCentury  |  Product Development

ROCKET resumes

The swift release of a clinical hold on Juno Therapeutics Inc .'s ROCKET trial notwithstanding, why and how high-dose fludarabine contributed to fatal neurotoxicity remains an unanswered - and important - question for the CAR...
07:00 , May 12, 2014 |  BioCentury  |  Finance

Vivid imaging

Vivid imaging Investors in ImaginAb Inc. 's $21 million series B round expect its lead agent will provide greater specificity and sensitivity in prostate cancer detection than CT or bone scans - and do so...
08:00 , Jan 16, 2014 |  BC Innovations  |  Cover Story

Putting on the brakes

The key safety concern with chimeric antigen receptors is their inability to distinguish whether healthy or malignant cells are expressing a target antigen. A group at the Memorial Sloan Kettering Cancer Center thinks it has...
08:00 , Jan 17, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Chimeric antigen receptors (CARs) that require dual-antigen binding for activation T cells engineered to express a CAR and a chimeric co-stimulatory receptor could enhance the...